Replies to post #5021 on BioCurex, Inc.(fka BOCX)

[great-grandma]

Half Full,

"We have been asked frequently about the progress of our major licensee. Confidentiality terms preclude us from making any specific comments at this time. We cannot speculate about launching dates, milestone dates or values. Nothing has changed since we signed the agreement with the exception of the work which is advancing. In the most general terms, we are very pleased with the way things are moving along."

It would be nice if they just re-affirmed the above. The release is dated Oct. 2005.

[Gold Seeker]

Why would ABT say anthing about RECAF right now? They have zero motivation to increase the value of your investment. As a matter of fact, they probably like the cheap price. If is stays cheap and Moro needs money, ABT might renegotiate the deal for less milestones, less royalties, and an exclusive just to get some needed money. I doubt you will see any change to the deal but as I said, ZERO motivation. Also any comments might trigger a feasibility milestone. Hopefully, Moro just idles along using minimum cash, hopes for another license and waits for ABT. IMO, that is his best choice and should be yours also.

As to foreign marketing, The USA market would have the majority of the sales even in a world wide market. The USA market for any drug or test is HUGE and Moro 's ability to raise cash is limited.

Bocxman, you are correct in one way on PIPES. It is bad enough that they are always deep discount but the really bad operators out of JP Turner have suckered naive CEO's into doing opened ended ones where they can drive the price down and trigger a lot of shares. Thinly traded stocks are in real danger for manipulation.

Bocxman, A question. Why would Moro establish Curex/Pacific Bioscience's to do contract work for BOCX? BOCX is paying for it anyway so why not set it up in house and save the middle man. Why is Moro insulating himself from BOCX other than for personal advantage?